Kornimate/medical-research-clean huggingface dataset:
dns-3379 vs. placebo in stroke rehabilitation

Conditions: Ischemic Stroke

Summary: this is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of dns-3379 on upper extremity motor recovery in subjects following ischemic stroke.


Eligibility criteria:
main inclusion criteria: * subjects who have experienced an ischemic stroke documented by ct or mri resulting in upper extremity deficit that warrants the need for rehabilitation therapy. * medically stable subjects, with expected survival \> 12 months, who are able to be randomized to study drug beginning between 1 and 52 weeks (i.e., 7 to 365 days) post-stroke. * mild to moderately severe upper extremity motor impairment. * mrs score of 1 to 4 from index stroke. * mini mental state examination (mmse) score of ≥ 22. main exclusion criteria: * residual motor deficit from any prior stroke * hemorrhagic stroke. ischemic stroke with limited hemorrhagic conversion (i.e., petechial hemorrhage or micro-hemorrhage) is acceptable. * severe or total sensory loss * moderate to severe aphasia and/or severe language deficits * excessive spasticity in the affected elbow or change in oral spasticity treatment drugs within 2 weeks before the screening visit * prior botulinum toxin injection to any portion of the affected arm in the prior 3 months before the screening visit * major and active neurological, psychiatric, or medical diagnosis that is not adequately controlled and would likely reduce the safety of study participation or impact the subject's ability to comply with study protocol procedures in the opinion of the investigator * any suicidal ideation during the subject's lifetime at any time prior to randomization including childhood (based on subject history), equivalent to type 2 on the columbia-suicide severity rating scale (c-ssrs) * received an investigational pharmacotherapy therapy within the past 3 months * heavy use of any tobacco-smoke emitting products (including but not limited to cigarettes, pipes, and cigars) within 30 days of baseline. * pregnant or lactating females

Keywords: stroke rehabilitation ischemic
chimeric antigen receptor (car)-modified t cell therapy in treating patients with acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: traditional standard treatments of b cell acute lymphoblastic leukemia is not perfect for fighting cancer. many people do not respond to the standard treatments of all. one possible treatment is chimeric antigen receptor (car) modified t cell infusions. this study aims to evaluate the safety and efficacy of novel carts (targeting cd19) in the treatment of refractory or recurrent all.the investigators start phase i study aimed to chemotherapy resistant or refractory acute lymphoblastic leukemia patients. the purpose of this study is to assess the safety and effectiveness of car-t cells in patients.

car-t has stronger effect of anti-tumor capacity. while people have been able to control the clinical complications now, so conducting car-t clinical trials has a strong demand and value. this study aims to evaluate the safety and efficacy of cd19-cart in treating refractory or recurrent all.

Eligibility criteria:
inclusion criteria: * age: 18-65 years * patients with cluster of differentiation 19 (cd19) positive b cell malignancies as confirmed by flow cytometry * refractory or relapsed b cell-acute lymphoblastic leukemia * no available curative treatment options (such as hematopoietic stem cell transplantation) * stage iii-iv disease * creatinine \< 2.5 mg/dl * aspartate transaminase-alanine transaminase ratio \< 3x normal * bilirubin \< 2.0 mg/dl * karnofsky performance status \>= 60 * expected survival time \> 3 months * adequate venous access for apheresis * ability to understand and provide informed consent exclusion criteria: * pregnant or lactating women * patients requiring t cell immunosuppressive therapy * active central nervous system leukemia * any concurrent active malignancies * patients with a history of a seizure disorder or cardiac disorder * patients with human immunodeficiency virus, hepatitis b or c infection * uncontrolled active infection
evaluation of procalcitonin (pct) as a marker of infection post living donated liver transplant

Conditions: Liver Transplant Infection

Summary: , the study aimed at assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed ldltrx.

all patients transferred from operative theatre to icu will be sedated, intubated \& ventilated. they will receive empiric antimicrobial prophylaxis upon admission \& early immunosuppression according to the clinical practice guidelines in our center, (appendix 1). preoperative patients' demographic data will be obtained. model for end-stage liver disease (meld) prior transplant, the primary cause of liver transplant. operative \& anesthetic details; operation time, units of blood, blood products transfusion, ischemic time, type of preservatives used, back table procedures, extra-hepatic procedure \& graft to recipient weight ratio will be recorded. postoperative patient evaluation will include; sequential organ failure assessment (sofa) on admission \& /48h. hemodynamic monitoring will include hourly measurement of heart rate, mean arterial pressure (map), temperature, central venous pressure (cvp), arterial oxygen saturation (sao2), daily total volume of fluid infused, urine output, fluid balance daily, blood gases / 6h \& daily mean values will be recorded till hospital discharge. routine laboratory workup includes biochemical markers of liver, kidney function and hematological parameters (complete blood count \& coagulation profile). patient evaluation for infection will be done through scheduled measurements of pct every other day during icu stay \& upon needed during the hospital stay. other markers of infections will be measured till hospital discharge as c-reactive protein (crp) every other day, daily total leukocyte count (tlc) \& band cells %. microbiological evidence of infection will be confirmed by cultures that will be regularly sampled every other day during icu stay \& upon any clinical or laboratory biomarker suggestive of infection. management of suspected infection; when pct value rising with clinical, radiological \&/or laboratory evidence of infection (tlc, crp, band%), culture from suspected site of infection will be withdrawn. if the source of infection is not evident, cultures from; blood, urine, sputum, surgical wound, drain \& nasal swab will be withdrawn \& empiric antimicrobial against gram +ve bacteria will be initiated. while the management of proven infection will be culture based antimicrobial initiation.

Eligibility criteria:
inclusion criteria: * including adult patients aged ≥18 years old who are recipients for living donated liver transplantation (ltx) at the department of liver transplant of national hepatology \& tropical medicine research institute (nhtmri), between january 2014 and january 2018 \& with no contraindications for early immunosuppression. exclusion criteria: * patients will be excluded from the study if they are readmitted or had primary graft nonfunction.
effectiveness of low-dose iron treatment in non-anaemic iron-deficient women

Conditions: Iron Deficiency (Without Anemia)

Summary: iron deficiency is common in switzerland and the main reason for anaemia. nearly one in five premenopausal women suffers from iron deficiency. low iron intake, reduced iron resorption or loss of blood are the main cause for iron deficiency. symptoms of iron deficiency, for example fatigue, weakness, headache or exercise intolerance are primarily due to anaemia, but the same symptoms may also be present in non-anaemic patients with low serum ferritin. consequently it is important to detect and treat non-anaemic iron deficiency. common side effects of oral iron supplementation are primarily gastrointestinal symptoms like nausea, vomiting, diarrhea or abdominal pain. there is a positive correlation between appearance of gastrointestinal symptoms and administered iron dose. to date, only few studies have investigated effectiveness of low-dose iron supplementation in different target groups. the aim of this study is to investigate if low dose iron supplementation with 12mg iron per day for 8 weeks is sufficient to increase serum ferritin levels into a normal range in healthy premenopausal women suffering from non-anaemic iron deficiency


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * female gender * premenopausal * age \> 18 years * regular menstrual cycle * bmi in normal range (18-25 kg/m²) * serum-ferritin \<30ng/ml * no anaemia * symptomatic iron deficiency in the past * no intake of dietary supplements exclusion criteria * intake of dietary supplements * pregnancy * hypermenorrhea * anaemia * serum-ferritin \>30ng/ml * bmi \ 25 kg/m² * chronic inflammatory diseases (e.g. colitis) * hypersensitivity to iron-supplements * psychiatric disorder
overal survival after tavi according to sarcopenia

Conditions: Sarcopenia; Aortic Valve Stenosis

Summary: the goal of this observational study is to compare the overal survival after transcatheter aortic valve implantation (tavi) according to sarcopenia status evaluated from preprocedural ct scans. the main question it aims to answer is: • is ct evaluated sarcopenia an independent predictor of overal survival after tavi?

the patients suffering from aortic valve stenosis, that are not eligible for cardiosurgery were indicated to miniinvasive transcatheter aortic valve implantation (tavi). the follow up of 930 patients were done in time interval from 1 to 11 years. in every patient the preprocedural ct scans were done. from these ct scans the l3 cross sections will be used for sarcopenia evaluation. then we will statisticaly evaluate the overal survival after tavi procedure in the relation with sarcopenia status. we will answer the main question: is ct evaluated sarcopenia an independent predictor of overal survival after tavi?

Eligibility criteria:
inclusion criteria: * patients udergone tavi procedure exclusion criteria: * patients with incomplete tavi procedure, patients without clinical follow up

Keywords: sarcopenia survival tavi
antibiotics, antibiotic resistance, and prescribing practices among periodontists: cross sectional kap study

Conditions: Antibiotic Resistance; Antibiotic Use; Periodontitis

Summary: antibiotic resistance is a global health threats that require attention from all healthcare providers. in periodontology, antibiotic is prescribed in many clinical situations. the aim of this study is to assess the followings among periodontists (1) the knowledge, attitude, and practices (kap) towards antibiotics and antibiotic resistance; (2) the prescribing practices of antibiotics in periodontal therapy; (3) the correlation between personal perception of antibiotics uses and the professional prescription patterns; and (4) the differences in antibiotics prescription in relation to the years of experience and the academic background.

the study is designed as a cross-sectional online-based questionnaire, and it will be distributed among periodontitis. the study will be conducted in egypt as a nationwide survey study. google form was used to develop online-based questionnaires.

Eligibility criteria:
inclusion criteria: * periodontists who practice in egypt. * must hold at least a master's degree in periodontology * willing to provide informed consent to participate in the study and agree to use the data for publication purposes. exclusion criteria: * periodontists who don not practice in egypt. * periodontists who don not hold postgraduate degree

Keywords: kap study antibiotics use antibiotic resistance prescribing practice periodontal therapy periodontists
relationships between exercise and emotion regulation on physical activity in frail older adults

Conditions: Mobility Limitation; Sedentary Lifestyle; Older Adults

Summary: frailty in older adults is a consequence of physical inactivity, which leads to poor physical function, disability and poor health outcomes. nearly 60% of older adults report inactivity. emotion regulation strategies have affective, cognitive and social consequences. positive emotions are significantly associated with a higher ability to perform activities of daily living. there is a gap in the understanding of how exercise influences the selection of emotion regulation strategies (avoidant vs. adaptive) in frail older adults. the investigators propose to examine the interactions between regular exercise, selection of emotional regulation strategies, and daily physical activity in frail sedentary older adults.

1. determine the choice of emotion regulation strategies used by frail sedentary older adults (60+ years; n=24). frailty will be defined as a gait speed \<0.8 m/sec. hypothesis: frail sedentary older adults will choose avoidant emotion regulation strategies. 2. examine whether a peer-led, community-based, group-exercise program lasting 12-weeks improves the selection of emotion regulation strategies in frail sedentary older adults as compared to those receiving support services (12/group). hypothesis: exercise will result in higher use of adaptive emotion regulation strategies than support services. 3. examine if improved selection of emotional regulation strategies with exercise translates into increased daily physical activity and reduced sedentary behavior by frail older adults as compared to those receiving support services. hypothesis: exercise will significantly increase daily physical activity and decrease sedentary behavior than support services. 4. determine if improvements in emotional regulation strategy selection and daily physical activity levels positively influence health and well-being (i.e. health status, physical function, mood, depressive symptoms, anxiety, and sense of loneliness and isolation). hypothesis: exercise-induced improvements in emotion regulation and increased daily physical activity will be associated with improved overall health and well-being as compared to support services.

Eligibility criteria:
inclusion criteria: * community-dwelling older adults 60+ years of age * men and women * frail older adults with impaired mobility (gait speed \< 0.8 m/sec) * sedentary older adults exclusion criteria: * unable to give consent * unable to exercise * unable to travel to the community site * unstable chronic conditions
granulocyte macrophage-colony stimulating factor (gm-csf) inhalation to improve host defense and pulmonary barrier restoration

Conditions: ARDS

Summary: this trial evaluates efficacy and safety of inhaled molgramostim (rhgm-csf) in 45 patients with pneumonia associated acute respiratory distress syndrome (ards). a third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. the patients will be followed for 28 days.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form by the patient or a legal representative according to local regulations 2. man or woman 18 to 75 years of age, inclusive 3. women who have been post-menopausal for more than 1 year or women of childbearing potential period using a highly efficient method of contraception (i.e. a method with less than 1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tube occlusion, vasectomized partner, sexual abstinence) during dosing and hospitalisation. women must have a negative serum or urine pregnancy test before the first dose of study medication and must not be lactating. 4. diagnosis of pneumonia-associated ards, where the underlying condition is community-acquired pneumonia (cap) or hospital-acquired pneumonia (hap) in patients not on invasive ventilation upon diagnosis of hap. 5. diagnosis of ards according to the berlin ards definition. 6. requirement for positive pressure ventilation (non-invasive or via endotracheal tube) for more than 72 hours in total with inspiratory oxygen concentration (fio2) ≥ 50% (or less when on additional ecmo therapy) not longer than 14 days exclusion criteria: 1. receiving vasopressors of \>100 µg/min 2. history of liver cirrhosis child pugh c, chronic hemodialysis (before severe pneumonia/ards), lung cancer 3. malignancy with expected survival time of less than 6 months 4. history of or listing for lung transplantation 5. highly immunosuppressive therapy or anti-malignant combination chemotherapy within 3 weeks prior to first dose of study drug 6. any anti-malignant chemotherapy within 24 hours prior to first dose of study drug 7. aids or known history of hiv infection 8. pregnancy 9. autoimmune thrombocytopenia, myelodysplastic syndromes with \> 20% marrow blast cells 10. history or presence of hypersensitivity or idiosyncratic reaction to molgramostim or to related compounds (i.e., growgen®, leucomax®, leukine™, topleucon™) 11. participation in another clinical trial within 90 days prior to the first dose of study drug

Keywords: acute lung injury, molgramostim, gm-csf, pneumonia, barrier restoration
injection of teriparatide to prevent hypocalcemia after parathyroidectomy in dialysis patients (terica).

Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis; Hypocalcemia; Hypoparathyroidism

Summary: this is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.

postoperative hypocalcemia is a common complication after parathyroidectomy (ptx) for secondary hyperparathyroidism in dialysis-dependent patients. it is known to be associated with significant drop of parathyroid hormone (ipth) level after surgery. thus, in the present study we test the hypothesis that reducing ipth difference before/after ptx with teriparatide injections immediately after surgery may alleviate clinical course of post-ptx hypocalcemia. this is a feasible study aimed to determine the sample size for further large-scale trial.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. patients with end-stage renal disease (esrd) receiving hemodialysis or peritoneal dialysis treatment \> 3 months prior surgery; 3. severe secondary hyperparathyroidism defined as ipth level \> 800 pg/ml, followed with hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or diffuse parathyroid hyperplasia confirmed with ct; 4. performed total parathyroidectomy with autotransplantation of the parathyroid tissue. exclusion criteria: 1. emergency surgery; 2. primary hyperparathyroidism as a cause of esrd; 3. scheduled (before surgery) blood transfusion; 4. re-operative surgery; 5. known allergy to the study drug. 6. malignant neoplasms of bone tissue (primary or metastatic).

Keywords: parathyroidectomy teriparatide parathyroid hormone
exploratory biomarker analysis of neoadjuvant chemoimmunotherapy followed by pulmonary resection in stage ii-iii non-small cell lung cancer

Conditions: Clinical Stage II to III Non-Small Cell Lung Cancer

Summary: 1. to explore tissue-based biomarkers to select patients who do not respond to neoadjuvant immunotherapy (non-responders) at the point of diagnosis 2. to explore blood-based non-invasive biomarkers to predict pathological complete response (pcr) before surgery

1. construction of a neoadjuvant chemoimmuntherapy cohort of resectable stage 2-3 lung cancer patients and acquisition of clinical-pathological-radiological data. 2. plasma from individual patient will be collected at preneoadjuvant and postneoadjuvant stages and ctdna analysis will be performed.

Eligibility criteria:
inclusion criteria: * histologically proven clinical stage ii-iii lung cancer patients * no driver mutations (egfr mutation and alk alteration) * whole body performance (ecog) 0-1 * those over 19 years of age * subject who submitted informed consent form exclusion criteria: * under 19 years of age * if there is a history of causing infection or other serious medical problems that impair the patient's function and make it difficult to comply with the study protocol. * patients for whom the investigator determines that the patient should not participate in the clinical trial because the patient is judged to be unable to comply with the clinical trial procedures and requirements (a person lacking medical capacity) * other patients (pregnant women, etc.) determined by the clinical trial director to be unsuitable for this clinical trial.

Keywords: nsclc neoadjuvant chemoimmunotherapy
pilot study on the use of artificial tears to treat dry eye in glaucoma patients

Conditions: Glaucoma; Dry Eyes

Summary: research indicates that many people who are being treated for glaucoma have dry eyes. the purpose of this study is to test the use of artificial tears to alleviate dryness signs and symptoms in people who are using medication to treat glaucoma. the study hypothesis is that the use of artificial tears will result in an improvement in clinical signs and symptoms associated with dry eyes.


Eligibility criteria:
inclusion criteria: * at least 17 years of age and has full legal capacity to volunteer; * has read and signed an information consent letter; * is willing and able to follow instructions and maintain the appointment schedule; * is a current non-contact lens wearer. * has previously been diagnosed with primary open angle glaucoma and is currently being treated with a topical therapeutic agent. * the glaucoma medication dosage and usage must have been the same for \>6 months. * shows a minimum score of 2 (sometimes) on the sesod questionnaire. * distance va of at least 20/40 in each eye with current spectacle correction. exclusion criteria: * is participating in any concurrent clinical or research study; * has any known active\* ocular disease and/or infection; except primary open angle glaucoma. * has a systemic condition that in the opinion of the investigator may affect a study outcome variable; * is using any systemic or topical medications (with the exception of glaucoma medication) that in the opinion of the investigator may affect a study outcome variable; * has known sensitivity to the diagnostic pharmaceuticals to be used in the study; * is pregnant, lactating or planning a pregnancy at the time of enrolment; * has undergone refractive error surgery; * is an employee of the centre for contact lens research; * has taken part in another (pharmaceutical) research study within the last 30 days; * is currently using artificial tears more than 3 times per day. * for the purposes of this study, active ocular disease is defined as infection or inflammation that requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.